Bruker Daltonics, November 2018

Learn more about the HCP analysis transitioning to a new phase

In the rapidly expanding arena of biotherapeutic analysis and bioprocess development, the analysis of host cell proteins (HCP) is transitioning to a new phase. HCPs are contaminants in biotherapeutic drug preparations, often at low ppm concentration levels, and must be monitored due to stability, efficacy and immunogenicity concerns. Often, these protein impurities will be considered Critical Quality Attributes (CQA) and can contribute to an overall risk assessment for the product.

Immunospecific assays such as ELISA are currently the gold standard for QC applications, but there are long lead times for new assays based on process changes. The main advantage of mass spectrometry is the ability for unbiased, highly sensitive detection, although this generally comes at the cost of very long run times.

In this presentation we show how PASEF (parallel accumulation and serial fragmentation), implemented on the Bruker timsTOF Pro, can be applied to HCP analysis to achieve the goal of rapid and sensitive detection with quality data.

We invite you to join this webinar to stay up-to-date on recent advancements in HCP analysis. Watch it whenever you want.

Further Reading

In Depth Analysis of Host Cell Proteins from Antibody Preparations using PASEF

Download App Note

High Throughput HCP Screening is here: > 50 HCPs identified in 21 minutes

Download Flash Note

Need more information? Contact us.